239 related articles for article (PubMed ID: 31319147)
21. Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines.
Habibi-Anbouhi M; Kafi Z; Ghazizadeh L; Kharazi S; Behdani M; Faraji F; Shokrgozar MA
Iran J Allergy Asthma Immunol; 2019 Oct; 18(6):679-687. PubMed ID: 32245312
[TBL] [Abstract][Full Text] [Related]
22. [Construction of a new anti-CD123 chimeric antigen receptor T cells and effect of anti-acute myeloid leukemia].
Wang ZZ; Lu Y; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Xiong DS; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):192-197. PubMed ID: 32311887
[No Abstract] [Full Text] [Related]
23. CD33, CD96 and Death Associated Protein Kinase (DAPK) Expression Are Associated with the Survival Rate and/or Response to the Chemotherapy in the Patients with Acute Myeloid Leukemia (AML).
Jiang Y; Xu P; Yao D; Chen X; Dai H
Med Sci Monit; 2017 Apr; 23():1725-1732. PubMed ID: 28391288
[TBL] [Abstract][Full Text] [Related]
24. Targeting Notch-1 positive acute leukemia cells by novel fucose-bound liposomes carrying daunorubicin.
Ono M; Takimoto R; Osuga T; Okagawa Y; Hirakawa M; Yoshida M; Arihara Y; Uemura N; Hayasaka N; Miura S; Matsuno T; Tamura F; Sato Y; Sato T; Iyama S; Miyanishi K; Takada K; Kobune M; Kato J
Oncotarget; 2016 Jun; 7(25):38586-38597. PubMed ID: 27233074
[TBL] [Abstract][Full Text] [Related]
25. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
Hutmacher C; Volta L; Rinaldi F; Murer P; Myburgh R; Manz MG; Neri D
Leuk Res; 2019 Sep; 84():106178. PubMed ID: 31326578
[TBL] [Abstract][Full Text] [Related]
26. Effect of Compound Zhebei Granule () combined with chemotherapy on surface markers of leukemia stem cell in patients with acute myeloid leukemia.
Wang J; Lai ZL; Chen XY; Li DY; Zhang YY; Ma W; Chu YT; Shi FQ; Yang L; Hou L
Chin J Integr Med; 2016 Jun; 22(6):438-44. PubMed ID: 26666761
[TBL] [Abstract][Full Text] [Related]
27. Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.
Laszlo GS; Harrington KH; Gudgeon CJ; Beddoe ME; Fitzgibbon MP; Ries RE; Lamba JK; McIntosh MW; Meshinchi S; Walter RB
Oncotarget; 2016 Jul; 7(28):43281-43294. PubMed ID: 27248327
[TBL] [Abstract][Full Text] [Related]
28. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
Tettamanti S; Marin V; Pizzitola I; Magnani CF; Giordano Attianese GM; Cribioli E; Maltese F; Galimberti S; Lopez AF; Biondi A; Bonnet D; Biagi E
Br J Haematol; 2013 May; 161(3):389-401. PubMed ID: 23432359
[TBL] [Abstract][Full Text] [Related]
29. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
Zhou L; Liu X; Wang X; Sun Z; Song XT
Leuk Res; 2016 Feb; 41():76-84. PubMed ID: 26740053
[TBL] [Abstract][Full Text] [Related]
30. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
Laszlo GS; Gudgeon CJ; Harrington KH; Dell'Aringa J; Newhall KJ; Means GD; Sinclair AM; Kischel R; Frankel SR; Walter RB
Blood; 2014 Jan; 123(4):554-61. PubMed ID: 24311721
[TBL] [Abstract][Full Text] [Related]
31. Targeting acute myeloid leukemia cells by CD33 receptor-specific MoS
Štefík P; Annušová A; Lakatoš B; Elefantová K; Čepcová L; Hofbauerová M; Kálosi A; Jergel M; Majková E; Šiffalovič P
Biomed Mater; 2021 Aug; 16(5):. PubMed ID: 34280914
[TBL] [Abstract][Full Text] [Related]
32. Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.
Boucher JC; Shrestha B; Vishwasrao P; Leick M; Cervantes EV; Ghafoor T; Reid K; Spitler K; Yu B; Betts BC; Guevara-Patino JA; Maus MV; Davila ML
Mol Ther Oncolytics; 2023 Dec; 31():100751. PubMed ID: 38075241
[TBL] [Abstract][Full Text] [Related]
33. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population.
Leyton JV; Hu M; Gao C; Turner PV; Dick JE; Minden M; Reilly RM
J Nucl Med; 2011 Sep; 52(9):1465-73. PubMed ID: 21816968
[TBL] [Abstract][Full Text] [Related]
34. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines.
Bailly JD; Muller C; Jaffrézou JP; Demur C; Gassar G; Bordier C; Laurent G
Leukemia; 1995 May; 9(5):799-807. PubMed ID: 7769842
[TBL] [Abstract][Full Text] [Related]
35. Acute myeloid leukemia fusion genes can be found in CD33-negative cells.
Chen Y; Liu Q; Xing H; Rao Q; Wang M; Mi Y; Wei H; Wang J
Int J Lab Hematol; 2022 Dec; 44(6):1111-1114. PubMed ID: 35915999
[TBL] [Abstract][Full Text] [Related]
36. Folate receptor targeted delivery of liposomal daunorubicin into tumor cells.
Ni S; Stephenson SM; Lee RJ
Anticancer Res; 2002; 22(4):2131-5. PubMed ID: 12174894
[TBL] [Abstract][Full Text] [Related]
37. SS30, a novel thioaptamer targeting CD123, inhibits the growth of acute myeloid leukemia cells.
Wang M; Wu H; Duan M; Yang Y; Wang G; Che F; Liu B; He W; Li Q; Zhang L
Life Sci; 2019 Sep; 232():116663. PubMed ID: 31323275
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-3 receptor α chain (CD123) is preferentially expressed in immature T-ALL and may not associate with outcomes of chemotherapy.
Du W; Li J; Liu W; He Y; Yao J; Liu Y; Lin J; Zheng J
Tumour Biol; 2016 Mar; 37(3):3817-21. PubMed ID: 26474588
[TBL] [Abstract][Full Text] [Related]
39. The past and future of CD33 as therapeutic target in acute myeloid leukemia.
Laszlo GS; Estey EH; Walter RB
Blood Rev; 2014 Jul; 28(4):143-53. PubMed ID: 24809231
[TBL] [Abstract][Full Text] [Related]
40. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia.
Venugopal S; Daver N; Ravandi F
Curr Hematol Malig Rep; 2021 Feb; 16(1):89-96. PubMed ID: 33630233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
